Hepatosplenic T-cell lymphoma in a patient with Crohn's disease

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 7, 2009, Pages 433-436

  Beigel, Florian ^a   Jürgens, Matthias ^a   Tillack, Cornelia ^a   Subklewe, Marion ^a   Mayr, Doris ^a   Göke, Burkhard ^a   Brand, Stephan ^a   Ochsenkühn, Thomas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOPHOSPHAMIDE; INFLIXIMAB; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANAMNESIS; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; COLON STENOSIS; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CUSHING SYNDROME; DEATH; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC SCREENING; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INFECTION COMPLICATION; LABORATORY TEST; LEUKOCYTE COUNT; MALE; PERIANAL ABSCESS; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECTUM FISTULA; REOPERATION; SIDE EFFECT; SPLENECTOMY; SPUTUM CULTURE; T CELL LYMPHOMA; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CROHN DISEASE; CYCLOPHOSPHAMIDE; FATAL OUTCOME; HUMANS; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; SPLENECTOMY; SPLENIC NEOPLASMS;

EID: 67650891605     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.87     Document Type: Article

References (17)

1. Sandborn, W. J. et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: A randomized trial. Ann. Intern. Med. 146, 829-838 (2007).
2. Farcet, J. P. et al. Hepatosplenic T-cell lymphoma: Sinusal/ sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 75, 2213-2219 (1990).
3. Jaffe, E. S. et al. (eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (IARC, Lyon, 2001).
4. Krenacs, L. et al. The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: Evidence of origin from lymphocytes involved in innate immunity. Blood 101, 3590-3593 (2003).
5. Jonveaux, P., Daniel, M. T., Martel, V., Maarek, O. & Berger, R. Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T gamma/delta lymphoma. Leukemia 10, 1453-1455 (1996).
6. Ohshima, K. et al. Hepatosplenic γδ T-cell lymphoma: Relation to Epstein-Barr virus and activated cytotoxic molecules. Histopathology 36, 127-135 (2000).
7. Rosh, J. R., Gross, T., Mamula, P., Griffiths, A. & Hyams, J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? Inflamm. Bowel Dis. 13, 1024-1030 (2007).
8. Shale, M., Kanfer, E., Panaccione R. & Ghosh, S. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut 57, 1639-1641 (2008).
9. Mudter, J. & Neurath, M. F. Apoptosis of T cells and the control of inflammatory bowel disease: Therapeutic implications. Gut 56 293-303 (2007).
10. Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
11. Beaugerie, L. et al. Excess risk of lymphoproliferative disorders (LPD)in inflammatory bowel diseases (IBD): Interim results of the CESAME cohort. Gastroenterology 134 (Suppl. 1), A116-A117 (2008).
12. Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C. & Lewis, J. D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54, 1121-1125 (2005).
13. van Assche, G. et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology 134, 1861-1868 (2008).
14. Belhadj, K. et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 102, 4261-4269 (2003).
15. + T-cell malignancies. Br. J. Haematol. 110, 188-196 (2000).
16. Mittal, S., Milner, B. J., Johnston, P. W. & Culligan, D. J. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur. J. Haematol. 76, 531-534 (2006).
17. Humphreys, M. R., Cino, M., Quirt, I., Barth, D. & Kukreti, V. Long-term survival in two patients with hepatosplenic T-cell lymphoma treated with interferon-α. Leuk. Lymphoma 29, 1-4 (2008).